SavedAdd your journal

Journals / Abant Tıp Dergisi / 2026 / Cilt: 4 Sayı: 1

Effect Of Metformın Therapy On Antı Mullerian Hormone Levels In Patıents Wıth Polycystıc Ovary Syndrome

Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi

Zeynep Kamalak(Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları Ve Doğum Anabilim Dalı)
Ayşe Çarlıoğlu(Turgut Özal Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Endokrinoloji Bilim Dalı)
Derya Akdeniz(Turgut Özal Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı)
Sema Uysal(Turgut Özal Üniversitesi Tıp Fakültesi Biyokimya Anabilim Dalı)
İlknur İnegöl Gümüş(Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları Ve Doğum Anabilim Dalı)
Nilgün Öztürk Turhan(Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları Ve Doğum Anabilim Dalı)
Pages
15–19
Publication Date
2015-01-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After metformin therapy, AMH was measured significantly higher in PCOS- untreated group and PCOS+ metformin group before treatment p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The polycystic ovary syndrome PCOS is a disorder of reproductive-aged women.
📊
Key Findings & Data:The objective of this prospective randomised study was to observe antimullarian hormone AMH levels in patients with PCOS after metformin therapy.METHODS: A total of eighty- four 84 consequtive patients diagnosed according to the criteria proposed in Rotterdam and twenty 28 healthy volunteers were included in the study.
💡
Conclusion & Impact:After metformin therapy, AMH was measured significantly higher in PCOS- untreated group and PCOS+ metformin group before treatment p
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Polikistik over sendromu · metformin · antimüllerian hormon

Abstract

OBJECTIVE: The polycystic ovary syndrome PCOS is a disorder of reproductive-aged women. The objective of this prospective randomised study was to observe antimullarian hormone AMH levels in patients with PCOS after metformin therapy.METHODS: A total of eighty- four 84 consequtive patients diagnosed according to the criteria proposed in Rotterdam and twenty 28 healthy volunteers were included in the study. Half of patients 42 were treated with 1. 7 gr/ day metformin for six months. The other patients n=42 were observed without therapy for six months and all laboratory tests were compared with control group after 6-month-period.RESULTS: AMH levels were similar in two patient groups before treatment. After metformin therapy, AMH was measured significantly higher in PCOS- untreated group and PCOS+ metformin group before treatment p

Özet

AMAÇ: Polikistik over sendromu, üretken çağdaki kadınlarda sık görülen bir klinik durumdur. Hiperinsülinemi ve insülin direnci, hastalığın patofizyolojisinde önemli bir antite olarak karşımıza çıkar. Çalışmamızın amacı; antimüllerian hormon AMH düzeylerinin metformin tedavisi sonrası değişimini incelemekti.YÖNTEMLER: Rotterdam kriterlerine göre Polikistik over tanısı alan 84 hasta ve 28 sağlıklı gönüllü çalışmaya alındı. Hastaların yarısı n=42 1,7 gr/gün metformin tedavisi alırken diğer 42 hasta tedavisiz izlendi. 6 aylık perioddan sonra hastaların laboratuar testleri karşılaştırıldı.BULGULAR: AMH düzeyleri tedavi öncesi benzerdi. Metformin tedavisi sonrası tedavi alan PCOS hastaları ve kontrol grubu AMH düzeyleri 6 aylık period sonrasında benzer düzeylerde bulundu. Tedavi edilmeyenlere göre 1.7 gr/gün metformin alan hastalarda AMH düzeyleri belirgin düşük olarak izlendi p

🔖

Cite This Article

Kamalak, Z., Çarlıoğlu, A., Akdeniz, D., Uysal, S., Gümüş, İ. İ., Turhan, N. Ö. (2015). Effect Of Metformın Therapy On Antı Mullerian Hormone Levels In Patıents Wıth Polycystıc Ovary Syndrome. Abant Tıp Dergisi, Cilt: 4 Sayı: 1, 15–19. https://doi.org/10.5505/abantmedj.2015.47550

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (30)

  1. Farah L, Lazenby AJ, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med 1999;44: 870–874.
  2. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. J Obstet Gynecol. 1994; 34: 67–72.
  3. Balen AH. The pathogenesis of polycystic ovary syndrome: the enigma unravels. Lancet 1999;354: 966- 967
  4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18: 774–800
  5. Cate, R.L., Mattaliano, R.J., Hession, C., Tizard, R., Farber, N.M., Cheung, A., Ninfa, E.G., Frey, A.Z., Gash, D.J., Chow, E.P., Fisher, R.A., Bertonis, J.M., Torres, G., Wallner, B.P., Ramachandran, K.L., Ragin, R.C., Manganaro, T.F., MacLaughlin, D.T. & Donahoe, P.K. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45: 685- 698.
  6. Teixeria J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr. Rev. 2001;22: 657- 674.
  7. Nestler JE, Jakubowicz DJ, Evans WS, Pasguali R. Effects of metformin spontaneous and clomiphene induced ovulation in the polycysticovary syndrome NEJM 1998; 338: 1876.
  8. Rajpert-De Meyts, E., Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 3836- 3844.
  9. Renato Pasquali, Alessandra Gambineri et al. Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism 2000; 85: 2767- 2774
  10. Annemarie de Vet, Joop S. E. Laven, Frank H. De Jong. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility And Sterility. 2002;77: 357- 362.
  11. M.E. Fallat, Y. Siow, M. Marra, C. Cook and A. Carrillo, Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis, Fertil Steril 1997; 77: 962–965
  12. C.L. Cook, Y. Siow, A.G. Brenner and M.E. Fallat, Relationship between serum mullerianinhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women, Fertil Steril 2002; 77 (1): 141–146
  13. Rajpert-De Meyts, E., Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism.1999; 84: 3836- 3844.
  14. Annemarie de Vet, Joop S. E. Laven, Frank H. De Jong. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility And Sterility. 2002;77: 357- 362.
  15. P. Pigny, E. Merlen and Y. Robert et al., Elevated serum level of anti- mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest, J Clin Endocrinol Metab 2003 7: 5957–5962
  16. de Vet A. Laven JS, deJong FH, Themmen AP;Fauser BC. Antimullerian Hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77: 357- 62.
  17. Laven JS, Mulders AG, Visser JA, Themmen AP, de Jong FH, Fauser BC. Antimullerian hormone serum concentrations in normoovulatory and anovulatory women. J Clin Endocrinol Metab 2004; 89:318- 23.
  18. Christine L. Cook, Yong Siow, Amy G.Brenner. Relationship between serum mullerianinhiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertility And Sterility. 2002; 77(1):141- 146.
  19. Somunkıran A, Yavuz T, Yücel O, Özdemir İ, Anti- Mullerian Hormone levels during hormonal contraception in women with polycycstic ovary syndrome. European Journal OF Obstetrics & Gynecology and Reproductive Biology 2007; 134: 196- 201.
  20. Luque- Ramirez M, Alvarez- Blasco F, Botella- Carretero JI, Martinez- Bermejo E, Lasuncion MA, Escobar- Morreale HF. Comparison of ethinyl- estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92: 2453- 61.
  21. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20(7):1820-6.
  22. Falbo A, Rocca M, Russo T, D'Ettore A, Tolino A, Zullo F, Orio F, Palomba S. Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3 (21):16
  23. Vicenzo De Leo, Antonio la Marca, Raoul Orvieto and Ginseppe Morgante. Effect of Metformin on Insulin- Like Growth Factor (IGF) 1 and IGF- Binding Protein 1 in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 1985 4: 1598- 1600.
  24. Santana LF, de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol. 2004; 19(2): 88- 96.
  25. A. La Marca, G. Stabile, A.C. Artenisio and A. Volpe, Serum anti-Mullerian hormone throughout the human menstrual cycle, Hum Reprod 2006 21: 3103–7
  26. Cate, R.L., Mattaliano, R.J., Hession, C., Tizard, R., Farber, N.M., Cheung, A., Ninfa, E.G., Frey, A.Z., Gash, D.J., Chow, E.P., Fisher, R.A., Bertonis, J.M., Torres, G., Wallner, B.P., Ramachandran, K.L., Ragin, R.C., Manganaro, T.F., MacLaughlin, D.T. & Donahoe, P.K. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45: 685- 698.
  27. Rajpert-De Meyts, E., Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 3836- 3844.
  28. Rajpert-De Meyts, E., Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism.1999; 84: 3836- 3844.
  29. de Vet A. Laven JS, deJong FH, Themmen AP;Fauser BC. Antimullerian Hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77: 357- 62.
  30. Laven JS, Mulders AG, Visser JA, Themmen AP, de Jong FH, Fauser BC. Antimullerian hormone serum concentrations in normoovulatory and anovulatory women. J Clin Endocrinol Metab 2004; 89:318- 23.